A carregar...
Lack of access to CDK4/6 inhibitors for premenopausal patients with metastatic breast cancer in Brazil: estimation of the number of premature deaths
PURPOSE: A CDK4/6 inhibitor (CDK4/6i) combined with endocrine therapy is the standard of care for patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) metastatic breast cancer (MBC). However, the incorporation of these agents into clinical practice remains challenging. This study...
Na minha lista:
| Publicado no: | Ecancermedicalscience |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Cancer Intelligence
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7434502/ https://ncbi.nlm.nih.gov/pubmed/32863875 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2020.1081 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|